CURX

NEW YORK, May 22, 2026 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces an investigation of potential securities claims on behalf of shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX) (the "Company" or "Curanex"). The investigation concerns whether Curanex and certain officers and/or directors have engaged in securities fraud or other unlawful business practices.

NEW YORK, May 18, 2026 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces an investigation of potential securities claims on behalf of shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX) (the "Company" or "Curanex"). The investigation concerns whether Curanex and certain officers and/or directors have engaged in securities fraud or other unlawful business practices.

Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated wasting condition with no FDA-approved therapies specifically indicated for the condition Jericho, New York, May 14, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX) ("Curanex" or the "Company"), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, today provided a first quarter 2026 business update highlighting continued progress with Phyto-N, the Company's lead drug candidate. Curanex is advancing Phyto-N toward a planned Investigational New Drug (“IND”) submission to the U.S. Food and Drug Administration (“FDA”) for ulcerative colitis in the fourth quarter of 2026.

Expanded case series includes advanced thymic carcinoma, small cell lung cancer, pancreatic cancer, end-stage liver cirrhosis, and end-stage renal disease